FDA Approves Rasonque for Pancreatic Cancer: When It’s Available and Cost
Summary
The FDA has approved Rasonque, an oral medicine for advanced pancreatic cancer that targets proteins driving tumor growth. The drug, developed by Revolution Medicines, has shown in trials to extend the survival of patients with metastatic pancreatic cancer compared to chemotherapy.Key Facts
- Rasonque (generic name daraxonrasib) is a once-daily pill approved for advanced pancreatic cancer treatment.
- It targets the RAS protein family, especially KRAS mutations, which are common in over 90% of pancreatic cancers.
- The FDA approved the drug about 6.5 months before the deadline and granted special designations to speed up approval.
- Rasonque is for adults whose cancer has worsened after prior treatment or who cannot use standard chemotherapy.
- The drug costs $39,800 for a 30-day supply at wholesale price; patient costs may vary with insurance and assistance programs.
- In clinical trials, patients on Rasonque lived a median of 13.2 months versus 6.7 months with chemotherapy, reducing death risk by 60%.
- Side effects were fewer and less severe than chemotherapy’s and included rash, diarrhea, nausea, and fatigue.
- Over 2,000 patients accessed the drug early through an expanded-access program before full approval.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
